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1  | INTRODUCTION
Viruses are the simplest form of life, carrying genetic materials and 
the capacity to efficiently enter target host cells. Because of these 
properties, numerous types of viruses have been adapted as gene 
transfer vectors,1‒3 for which purpose adenoviruses have been well 
studied and characterized. Adenoviruses are large, double‐stranded 
DNA viruses exhibiting tropism for many human tissues, such as 
bronchial epithelia, hepatocytes, and neurons. Moreover, adenovi‐
ruses can transduce nonreplicating cells and be grown to high titers 
in vitro, which allows for their potential clinical use. Replication‐de‐
fective adenoviruses can be produced at high titers and have been 
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Abstract
Replication‐selective tumor‐specific viruses represent a novel approach for treat‐
ing neoplastic diseases. These vectors are designed to induce virus‐mediated lysis 
of tumor cells after selective intracellular virus propagation. For targeting cancer 
cells, the use of tissue‐ or cell‐specific promoters that are expressed in diverse tumor 
types but silent in normal cells is required. Human telomerase is highly active in more 
than 85% of primary cancers, regardless of tissue origin, and its activity is closely 
correlated with human telomerase reverse transcriptase (hTERT) expression. We 
constructed an attenuated adenovirus 5 vector (telomelysin, OBP‐301) in which the 
hTERT promoter element drives expression of E1 genes. As only tumor cells that ex‐
press the telomerase can activate this promoter, the hTERT proximal promoter allows 
for preferential expression of viral genes in tumor cells, leading to selective viral rep‐
lication and oncolytic cell death. Upon US Food and Drug Administration approval, 
a phase 1 dose‐escalation study of intratumoral injection of telomelysin for various 
solid tumors has been completed to confirm the safety, tolerability, and feasibility of 
the agent. Moreover, we found that adenoviral E1B 55‐kDa protein in telomelysin 
inhibits the radiation‐induced DNA repair machinery. Thus, tumor cells infected with 
telomelysin could be rendered sensitive to ionizing radiation. Recently, we assessed 
the safety and efficacy of intratumoral injection of telomelysin with radiotherapy in 
esophageal cancer patients not suited for standard treatments. This review highlights 
some very promising clinical advances in cancer therapeutic technologies using tel‐
omerase‐specific oncolytic virotherapy.
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successfully used to express genes in eukaryotic cells.4,5 A variety of 
adenoviral gene therapy agents has been tested in various studies 
using in vitro and animal models. The tolerability, safety, and poten‐
tial beneficial effects of these agents have been described for dif‐
ferent target diseases6,7 however, the three‐dimensional spread of 
replication‐deficient adenoviruses after intratumoral administration 
might be less than ideal.
Oncolytic viruses that can selectively replicate in tumor cells 
and lyse infected cells have been extensively investigated as novel 
anticancer agents.8,9 These vectors are designed to induce virus‐
mediated lysis of tumor cells after selective intracellular propaga‐
tion while remaining innocuous to normal tissues.10 The optimal 
treatment of human cancers requires improvement of the thera‐
peutic ratio to increase the cytotoxicity to tumor cells and decrease 
that against normal cells. This may not be an easy task, because 
the majority of normal cells surrounding tumors are sensitive to 
cytotoxic agents. Thus, to establish reliable therapeutic strategies 
for human cancers, it is important to seek genetic and epigenetic 
targets present only in cancer cells. One targeting strategy involve 
the use of tissue‐specific promoters to restrict gene expression or 
virus replication to specific tissues. A large number of different tis‐
sue‐specific promoters such as prostate‐specific antigen (PSA),11 
Mucin 1,12 osteocalcin,13 L‐plastin,14 midkine,15 and E2F‐116 have 
been used for virotherapy applications. However, for targeting 
tumors derived from various tissues, tumor‐specific, rather than 
tissue‐specific, promoters would be more advantageous. For ex‐
ample, the promoter for human telomerase reverse transcriptase 
(hTERT) is highly active in most tumor cells but inactive in normal 
somatic cells.
2  | TELOMERASE ACTIVITY FOR 
TRANSCRIPTIONAL CANCER TARGETING
One of the hallmarks of cancer is the unregulated proliferation of 
specific cell populations, which eventually affects normal cellular 
function throughout the body, and this is almost universally cor‐
related with telomerase reactivation. Telomerase is a ribonucleo‐
protein complex that mediates the addition of TTAGGG repeats to 
the telomeric ends of chromosomes. The enzyme consists of three 
components: an RNA subunit (known as hTR, hTER, or hTERC),17 
telomerase‐associated protein (hTEP1),18 and the catalytic subunit 
(hTERT).19,20 Both hTR and hTERT are required for the reconstitu‐
tion of telomerase activity in vitro21 and thus represent the minimal 
catalytic core of telomerase in humans.22 However, although hTR is 
widely expressed in embryonic and somatic tissues, hTERT expres‐
sion is tightly regulated and not detectable in most somatic cells. 
The strong association between telomerase activity and malignant 
tissues suggests that telomerase is a plausible target for the treat‐
ment of cancer.23 Thus, the hTERT proximal promoter can be used 
as a molecular switch for the selective expression of target genes 
in tumor cells, as almost all advanced human cancer cells express 
telomerase, whereas most normal cells do not.24,25
3  | GENETIC ENGINEERING OF AN 
HTERT PROMOTER‐DRIVEN ONCOLYTIC 
ADENOVIRUS
The use of modified adenoviruses that replicate and complete their 
lytic cycles preferentially in cancer cells is a promising strategy for 
the treatment of cancer. One approach to achieve tumor specificity 
of viral replication is based on the transcriptional control of genes 
that are critical for virus replication, such as E1A and E1B. The cata‐
lytic subunit of telomerase, hTERT, is expressed in the majority of 
human cancers, and the hTERT promoter is preferentially activated 
in a variety of human cancer cells.26 Therefore, the hTERT promoter 
may be a suitable regulator of adenoviral replication. It was previ‐
ously reported that transcriptional control of E1A expression by the 
hTERT promoter restricts adenoviral replication to telomerase‐posi‐
tive tumor cells, resulting in efficient lysis of the tumor cells.27‒30
We also examined the adenovirus E1B gene, which is expressed 
early in viral infection, and its gene product inhibits E1A‐induced p53‐
dependent apoptosis, which in turn promotes the cytoplasmic accu‐
mulation of late viral messenger RNA (mRNA), leading to a shutdown 
of host cell protein synthesis. In most vectors that replicate under tran‐
scriptional control of the E1A gene, including hTERT‐specific oncolytic 
adenoviruses, the E1B gene is driven by the endogenous adenovirus 
E1B promoter. However, it was previously reported that transcrip‐
tional control of both the E1A and E1B genes by a single tumor‐specific 
promoter with the use of an internal ribosome entry site significantly 
improves the specificity and therapeutic index in particular human 
tumor cells.31 Thus, we developed telomelysin (OBP‐301), in which the 
tumor‐specific hTERT promoter regulates expression of both the E1A 
and E1B genes (Figure 1). Telomelysin is expected to control viral repli‐
cation more stringently, thereby providing greater therapeutic efficacy 
against tumor cells, as well as attenuated toxicity in normal tissues.32
4  | PRECLINICAL STUDIES OF THE 
HTERT PROMOTER‐DRIVEN ONCOLYTIC 
ADENOVIRUS
In preclinical experiments, telomelysin‐induced selective E1A and E1B 
expression in cancer cells, which resulted in virus replication at 5‐6 logs 
by 3 days after infection, but telomelysin replication was attenuated 
up to 2 logs in cultured normal cells.32 In vitro cytotoxicity assays dem‐
onstrated that telomelysin efficiently kills both epithelial and mesen‐
chymal types of malignant tumor cells (including those of lung cancer, 
gastric cancer, esophageal cancer, colorectal cancer, head and neck 
cancer, hepatic cancer, cervical cancer, breast cancer, osteosarcoma, 
pancreas cancer, prostate cancer, melanoma, and mesothelioma) in a 
dose‐dependent manner (Figure 2).33 In addition, intratumoral injec‐
tion of telomelysin in subcutaneous and orthotopic xenograft tumor 
models was efficacious in treatment of both primary tumors32,34 and 
regional lymph node metastasis.35,36 Indeed, when telomelysin was 
intratumorally injected into human colorectal tumors orthotopically 
implanted into the rectum in nude mice, telomelysin caused viral 
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spread into the regional lymphatic area and selectively replicated in 
neoplastic lesions, resulting in tumor cell‐specific death in metastatic 
lymph nodes.35 Thus, telomelysin not only exhibits features that make 
it desirable for use as an oncolytic therapeutic agent, the proportion 
of cancers potentially treatable using telomelysin is extremely high.
To further enhance the antitumor effect of telomelysin‐based on‐
colytic virotherapy, we evaluated the therapeutic potential of telome‐
lysin in combination with conventional radiotherapy. Ionizing radiation 
primarily induces double‐strand breaks (DSBs) in DNA molecules. 
Radiosensitization can result from a therapeutic increase in DNA DSBs 
or inhibition of their repair. The MRN complex, consisting of Mre11, 
Rad50, and NBS1, is quickly stimulated by DSBs and directly activates 
ataxia‐telangiectasia mutated (ATM), an important signal transducer in 
the DNA damage repair response, which involves DNA repair and cell 
cycle checkpoints.37 Therefore, defects in the MRN complex induce 
hypersensitivity to DNA damage.38 We found that expression of the 
MRN complex in cancer cells decreased after telomelysin infection 
when E1B 55‐kDa protein expression began, leading to inhibition of 
ATM phosphorylation by ionizing radiation and inhibition of DNA re‐
pair (Figure 3). Telomelysin infection apparently sustains elevated lev‐
els of γH2AX (a hallmark of DNA DSBs) for longer periods in irradiated 
tumor cells. These findings indicate that tumor cells infected with telo‐
melysin could be rendered sensitive to ionizing radiation.39
5  | CLINICAL APPLICATION OF THE 
HTERT PROMOTER‐DRIVEN ONCOLYTIC 
ADENOVIRUS AS MONOTHERAPY
Many clinical trials of adenoviruses testing their oncolytic properties 
are well underway (Table 1).40‒44 To explore the clinical application 
of telomelysin, Oncolys BioPharma Inc. was established in March 
2004 as an Okayama University‐launched bio‐venture company. 
Based on preclinical studies, an open‐label, phase 1 dose‐escala‐
tion study of intratumoral injection of telomelysin was initiated in 
the USA to validate the safety, tolerability, and feasibility of telo‐
melysin as monotherapy in patients with advanced solid tumors.45 
The trial commenced following approval by the US Food and Drug 
Administration in October 2006. The doses of telomelysin were 
escalated in 1‐log increments from low to high virus particles (vp). 
Sixteen patients with a variety of solid tumors, such as melanoma, 
head and neck cancer, breast cancer, lung cancer, and sarcomas, 
F I G U R E  1   Structures of telomerase‐specific oncolytic adenoviruses. In telomelysin (OBP‐301), the human telomerase reverse 
transcriptase (hTERT) promoter element drives the expression of E1A and E1B linked with internal ribosome entry site. OBP‐702 is a 
telomerase‐specific replication‐competent adenovirus variant, in which the Egr‐1 promoter drives expression of the wild‐type p53  
(wt‐p53) gene inserted into the E3 region. Upper panel, scheme of the proximal hTERT promoter. Putative protein binding sites for various 
transcriptional factors are indicated. ITR, inverted terminal repeat
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were treated with a single‐dose intratumoral injection of telomelysin 
and then monitored over 1 month.
All patients received telomelysin without dose‐limiting toxicity. 
Common grade 1 and 2 toxicities included injection site reactions (pain, 
induration) and systemic reactions (fever, chills). Pharmacokinetic 
and biodistribution data for telomelysin were of particular interest. 
Circulating viral DNA was transiently (<6 h after injection) detected in 
plasma from 13 of 16 patients within 24 h after injection. This dose‐
dependent initial peak in circulating virus titer was followed by a rapid 
decline; however, three patients demonstrated evidence of prolonged 
viral replication through detection of viral DNA in plasma on days 7 
and 14, suggesting the replication of telomelysin in primary tumors. In 
one of these patients, the injected malignant lesion and loco‐regional 
uninjected satellite nodules disappeared, fulfilling the definition of a 
complete response (CR) at day 28. Eleven patients satisfied RECIST 
criteria for stable disease response in the injected lesion at day 28, 
whereas three patients had progressive disease, and two patients 
were unevaluable. Six patients exhibited reductions in tumor size of 
6.6%‐33%, and one of these patients exhibited a 33% reduction in 
the size of the injected lesion at day 28 and 56.7% reduction at day 
56. These clinical data suggest that telomelysin is well‐tolerated and 
warrants further clinical studies of its use in treating solid cancers.
6  | MULTIDISCIPLINARY APPROACH 
USING THE HTERT PROMOTER‐DRIVEN 
ONCOLYTIC ADENOVIRUS
The advantage of combination therapy with telomelysin plus conventional 
radiotherapy is that the areas in which each treatment demonstrates its 
F I G U R E  2   Oncolytic effects of telomelysin in vitro on a variety of human cancer cell lines.33 Cells were infected with telomelysin at 
indicated multiplicity of infections (MOI) values, and surviving cells were quantitated over 5 days by XTT assay. Data are mean ±SD
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therapeutic effect overlap. We previously demonstrated that intratumor‐
ally injected telomelysin expressing the GFP gene effectively traffics to 
the regional lymph nodes, as viral replication produced green fluores‐
cent protein‐associated fluorescence signals in metastatic lymph nodes 
in orthotopic human colorectal and oral cancer xenograft models.46,47 
Therefore, we hypothesize that intratumoral administration of telomely‐
sin would radiosensitize both primary tumors and regional lymph nodes.
An open‐label, phase 1, dose‐escalation study was conducted 
in esophageal cancer patients to further determine the feasibility, 
efficacy, and pharmacokinetics of telomelysin in combination with 
radiotherapy (UMIN 000010158; Figure 4). Thirteen patients with 
histologically confirmed esophageal cancer who were deemed unfit 
to receive standard therapies such as surgery and chemotherapy were 
enrolled into this study. Virus administration was performed by intra‐
tumoral injection of the primary or metastatic tumor via a flexible en‐
doscope. Study treatment consisted of intratumoral needle injections 
of telomelysin on days 1, 18, and 32 of treatment. Radiation therapy 
was administered concurrently over 6 weeks, beginning on day 4, to a 
total of up to 60 Gy. Virus distribution and shedding into the body flu‐
ids, including the saliva, sputum, urine, and plasma, were monitored 
using a quantitative DNA‐polymerase chain reaction assay.
Of 13 patients, seven, three, and three patients were included in co‐
horts treated with 10,10,11 and 1012 vp of telomelysin, respectively. The 
patient group comprised 10 men and three women, with a median age 
of 79.7 years (range, 53‐92 years). Common grades 1 and 2 toxicities 
included fever, esophagitis, pneumonitis, anorexia, constipation, and 
gastroesophageal reflux. All patients developed a transient, self‐limited 
lymphopenia. Distribution studies revealed the presence of viral DNA in 
five of the six patients who received 1011 or 1012 vp of telomelysin, but 
this was rarely detected in the gargle, saliva, and urine. Eight patients 
had a local CR; all of these patients exhibited no viable malignant cells in 
biopsy specimens. Three patients had a partial response. The objective 
response rate was 91.7%. The clinical CR rate was 83.3% in stage I and 
60.0% in stages II and III. Histopathologic examination of post‐treatment 
specimens showed massive infiltration of CD8+ cells in three partial re‐
sponse tumors. These findings indicate that treatment involving multiple 
F I G U R E  3   Molecular mechanism of telomelysin‐induced radiosensitization. The MRN complex plays a role as an upstream sensor in 
response to DNA double‐strand breaks. Degradation of the MRN complex by E1B 55‐kDa protein prevents ataxia‐telangiectasia mutated 
(ATM) autophosphorylation and signaling, leading to inhibition of the ATM‐dependent G2/M checkpoint
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TA B L E  1   Oncolytic adenoviruses in clinical testing
Oncolytic adenovirus Serotype Mechanism of action Indication(s) Clinical phase Ref.
CG0070 Adenovirus type 5 Human E2F‐1 promoter drives E1A 
gene
Bladder Phases I/II 40
Armed by the addition of the GM‐CSF 
gene
DNX‐2401/Ad∆24‐RGD 
(tasadenoturev)
Adenovirus type 5 E1A‐∆24 mutation in pRb‐binding 
site
Brain Phases I & II 41
Integrin‐binding RGD motif
ColoAd1 (enadenotucirev) Adenovirus type 
3/11p
Group B Ad11p/Ad3 chimeric 
adenovirus
Solid tumors Phases I & I/II 42
ONCOS‐102 Adenovirus type 5/3 E1A‐∆24 mutation in pRb‐binding 
site
Solid tumors Phases I & I/II 43
Pseudotyped with Ad3 knob
Armed by the addition of the GM‐CSF 
gene
VCN‐01 Adenovirus type 5 E1a mutated in the pRB‐binding site Pancreatic 
cancer
Phase I 44
Retargeting RGDK modification of 
the fiber
Expression of hyaluronidase
OBP‐301 (telomelysin) Adenovirus type 5 Human telomerase reverse tran‐
scriptase promoter drives E1 genes
Esophageal 
cancer
Phases I/II & II 45
HCC, melanoma
F I G U R E  4   Schematic outline of strategies for treating esophageal cancer. A. Synopsis of the study design and objectives. B. Schematic 
illustration of the treatment schedule. Patients with esophageal cancer who are not eligible for standard treatments receive intratumoral 
needle injections of telomelysin on days 1, 18, and 32. Radiation therapy is administered concurrently over 6 weeks, beginning on day 4, up 
to a total of 60 Gy
402  |     FUJIWARA
courses of endoscopic telomelysin injection in combination with radio‐
therapy is feasible and provides clinical benefits in patients with esoph‐
ageal cancer, particularly those who are unfit for standard treatments.
7  | NEXT‐GENERATION 
MULTIFUNCTIONAL HTERT PROMOTER‐
DRIVEN ONCOLYTIC ADENOVIRUS
Oncolytic viruses armed to express several types of therapeutic 
transgenes have been reported.48,49 Among candidate therapeutic 
transgenes, the tumor suppressor p53 gene is particularly potent and 
exhibits a variety of effects, including induction of cell cycle arrest, 
apoptosis, senescence, and DNA repair.50 Indeed, a p53‐express‐
ing replication‐deficient adenovirus (Ad‐p53, Advexin) was shown 
to induce antitumor effects both in vitro and in vivo,51‒53 as well as 
in various clinical studies.54,55 Therefore, to develop a next‐genera‐
tion hTERT promoter‐driven oncolytic adenovirus, we modified telo‐
melysin (OBP‐301) to express the wild‐type p53 tumor suppressor 
gene (OBP‐702; Figure 1) and compared the antitumor activity of 
OBP‐702 with that of telomelysin.56,57
The antitumor effects of OBP‐702 and telomelysin were com‐
pared using telomelysin‐sensitive and ‐resistant human cancer cells. 
OBP‐702 suppressed the viability of both telomelysin‐sensitive and 
‐resistant cancer cells more efficiently than telomelysin. OBP‐702 
exhibited greater induction of apoptosis of cancer cells compared to 
telomelysin and replication‐deficient Ad‐p53. Adenovirus E1A‐me‐
diated miR‐93/106b upregulation induced p21 suppression followed 
by MDM2 downregulation, leading to p53‐mediated apoptosis in 
OBP‐702‐infected cells. p53 overexpression enhanced adenovi‐
rus‐mediated autophagy via activation of the damage‐regulated 
autophagy modulator (DRAM). Moreover, OBP‐702 significantly 
suppressed tumor growth in subcutaneous and orthotopic tumor 
xenograft models compared to monotherapy with telomelysin or 
Ad‐p53. These findings suggest that OBP‐702‐mediated p53 trans‐
activation is a promising antitumor strategy for inducing both apop‐
totic and autophagic cell death pathways via regulation of microRNA 
and DRAM in human cancers.
To produce high‐titer virus in quantities required for clinical tri‐
als, large‐scale manufacturing of OBP‐702 is ongoing under Good 
Manufacturing Practice conditions.
8  | CONCLUSIONS AND PERSPECTIVES
Significant advances have been made in our understanding of the mo‐
lecular aspects of human gastrointestinal cancers and the develop‐
ment of technologies for viral genome modification. Transcriptional 
targeting is a powerful tool that enables tumor selectivity in cancer 
therapy, and the hTERT promoter‐driven oncolytic adenovirus we 
developed exhibits more specific targeting potential due to the am‐
plifying effects of viral replication.
A promising future application for telomelysin includes com‐
bination therapy with conventional approaches such as radiother‐
apy, chemotherapy, surgery, and immunotherapy. Indeed, in April 
2019, the Japanese Ministry of Health, Labour and Welfare desig‐
nated telomelysin in combination with radiotherapy an innovative 
pharmaceutical product under the SAKIGAKE Designation System. 
Designated products are eligible for prioritized consultation ser‐
vices, with a reduction in the premarket review period to as short as 
6 months, half the standard review period of 12 months. Moreover, 
Oncolys BioPharma Inc. granted an exclusive license to Chugai 
Pharmaceutical Co., Ltd., one of Japan's leading research‐based 
pharmaceutical companies, concerning the development, manufac‐
ture, and marketing of telomelysin in Japan and Taiwan. It is expected 
these events will accelerate the clinical development of telomelysin.
Clinical trials of telomelysin in combination with immunotherapy 
or chemoradiotherapy are also underway. An open‐label, phase 1 
study (EPOC1505) has been conducted to evaluate the safety and 
efficacy of telomelysin with anti‐programmed death 1 (PD‐1) an‐
tibody, pembrolizumab, in patients with advanced solid tumors. A 
phase 2 study of telomelysin in combination with pembrolizumab 
for esophagogastric adenocarcinoma was initiated in May 2019 at 
Weill Cornell Medical College in the USA. Moreover, NRG Oncology, 
a non‐profit research organization in the USA, is planning a phase 1 
study of telomelysin combined with definitive chemoradiation con‐
sisting of carboplatin/paclitaxel for treating locally advanced esoph‐
ageal cancer in patients who are medically inoperable.
The field of targeted oncolytic virotherapy has progressed con‐
siderably, such that it is rapidly gaining medical and scientific accep‐
tance. Although some conceptual and regulatory problems remain 
to be solved, ongoing and future clinical studies are expected to pro‐
vide important data that will lead to further substantial progress in 
human gastrointestinal cancer therapies.
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